Basic information Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Biochemical Reagents Agonist Inhibitors Momelotinib sulfate

1/1

Momelotinib sulfate NEW

$46.00 2mg

$77.00 5mg

Min. Order
Purity
Cas No1056636-06-6
Supply Ability10g
Update time2026-04-14

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

VIP4Y

United States

United States

show more

Enterprise Verified

Business Bank account Basic Contact Infomation Business Address Trade Company

Chemical Properties

Product Name	Momelotinib sulfate
CAS No	1056636-06-6
EC-No
Min. Order
Purity
Supply Ability	10g
Release date	2026/04/14

Product Introduction

Bioactivity

Name	Momelotinib sulfate
Description	Momelotinib sulfate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.
In vitro	Momelotinib sulfate inhibits growth of Ba/F3-JAK2V617F and Ba/F3-MPLW515L cells (IC50: 200 nM) or human erythroleukemia (HEL) cells (IC50: 1.5 μM). However, it has considerably less activity against BCR-ABL harboring K562 cells (IC50=58 μM) and FLT3 mutation harboring MV4-11 cells (IC50: 3 μM). Proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated with IL-3 is inhibited (IC50: 1.4 μM). This is same as the established role of IL-3-dependent signaling in the parental cell line [1].
In vivo	Administering Momelotinib sulfate at doses of 50 and 100 mg/kg had minimal impact on peripheral blood counts over 8 weeks. The median peak plasma concentrations reached 7.1 μM and 32.1μM for the lower and higher doses, respectively, with a 2-hour half-life. Trough levels were observed at 10nM (25 mg/kg) and 900nM (50 mg/kg) 12 hours post-administration. The compound demonstrated high plasma concentrations after oral intake (Cmax= 40.4 μM; Tmax=4 h), suggesting high oral bioavailability. This is likely due to its low blood clearance rate (6.3 mL/min/kg), indicating reduced hepatic first-pass metabolism. In a study, by day 34 post-transplantation, white blood cell counts and hematocrit values in Balb/c mice exceeded the normal range by more than one standard deviation (SD). Subsequent treatment with 25 mg/kg or 50 mg/kg Momelotinib sulfate, or a vehicle control, initiated a rapid decrease in white cell counts within six days and a decrease in hematocrit after 20 days, showing the drug's efficacy in modulating hematologic parameters.
Storage	Shipping with blue ice/Shipping at ambient temperature.
Solubility Information	DMSO : 6.2 mg/mL (10.15 mM), Sonication is recommended.
Keywords	Momelotinib sulfate \| JAK3 \| JAK2 \| JAK1 \| CYT-387 Sulfate \| CYT387 Sulfate \| CYT 387 Sulfate
Inhibitors Related	Stavudine \| Aceglutamide \| Hemin \| Urea \| Tamoxifen \| Guanidine hydrochloride \| Hydroxychloroquine \| Metronidazole \| Formamide \| Paeonol \| Naringin \| Alginic acid

show more

Company Profile Introduction

You may like

Recommended supplier

Send Inquriy